Leprosy Mailing List – October 19, 2019
Ref.: (LML) Single-dose rifampicin PEP increased the risk of MB disease
From: Erik Post, Jakarta, Indonesia
Dear Pieter,
Can the Maltalep 2019 report be published on the LM?
Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: A cluste r randomized controlled trial. Renate Richardus, et al. https://www.ijidonline.com/article/S1201-9712(19)30365-0/pdf
A lot of criticism is coming from it, but we have no idea how solid the methods and data are to support (or not) the claims that SDR-PEP would increase the number of MB cases on top and above current incidence. I find it hard to believe, as the causal pathway is obscure.
It is not the first time that Almeida is claiming things that are not well substantiated, but rather an opinion for which supportive data is then found. For the LML public it would be good if they can judge for themselves. I agree strongly with Cairns that these things should be peer-reviewed and then published if it holds truth.
Hope you are able to make this accessible?
Cheers,
Erik Post
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/4b660af9-1195-4592-9d0c-7e7908449e7f%40googlegroups.com.
No comments:
Post a Comment